AOD-9604 vs CagriSema
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
Also: Semaglutide + Cagrilintide
A combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | AOD-9604 | CagriSema |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | AOD-9604 mimics the lipolytic (fat-burning) effects of growth hormone without affecting blood sugar or tissue growth. It stimulates lipolysis and inhibits lipogenesis by interacting with beta-3 adrenergic receptors on fat cells. | Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1. |
| Common Dosing | 300 mcg daily Once daily, usually morning fasted | Limited community data available See research protocols |
| Administration | Subcutaneous injection or oral (studied both) | Subcutaneous injection weekly |
| Typical Duration | 12-24 weeks in studies | Long-term use expected |
| Best Time to Take | Morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Clinical trials showed modest weight loss effects but failed to meet primary endpoints for FDA approval. Some studies show cartilage regeneration potential. Research demonstrates safety profile similar to placebo with no significant GH-like side effects. | Phase 3 REDEFINE 1 trial showed 22.7% weight loss at 68 weeks, significantly outperforming semaglutide alone (15.8%). NDA submitted to FDA in December 2025. If approved, expected to become the leading obesity treatment. |
Frequently Asked Questions: AOD-9604 vs CagriSema
What is the difference between AOD-9604 and CagriSema?
AOD-9604 is a weight loss peptide that a modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full gh. CagriSema is a weight loss peptide that a combination of semaglutide and cagrilintide (amylin analog). the most effective weight loss drug candidate, showing 22.7% body weight reduction in phase 3 trials - superior to any single-agent glp-1. The main differences lie in their mechanisms of action and clinical applications.
Which is better, AOD-9604 or CagriSema?
Neither is universally "better" - the choice depends on your specific goals. AOD-9604 is typically used for weight loss purposes, while CagriSema is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can AOD-9604 and CagriSema be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using AOD-9604 and CagriSema together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of AOD-9604 and CagriSema is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.